Hedgehog signaling pathway: Development of antagonists for cancer therapy

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The hedgehog pathway, initially discovered in Drosophila by two Nobel laureates, Dr. Eric Wieschaus and Dr. Christiane Nüsslein-Volhard, is a major regulator for cell differentiation, tissue polarity, and cell proliferation. Studies from many laboratories - including ours - reveal activation of this pathway in most basal cell carcinomas and nearly one third of extracutaneous human cancers, including medulloblastomas and gastrointestinal and prostate cancers. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. This review discusses the current understanding of the hedgehog signaling pathway and its activation in human cancers. It also discusses putative and confirmed signaling antagonists and their perspectives in therapeutic applications.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalCurrent Oncology Reports
Volume10
Issue number2
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Hedgehogs
Neoplasms
Medulloblastoma
Gastrointestinal Neoplasms
Basal Cell Carcinoma
Drosophila
Cell Differentiation
Prostatic Neoplasms
Therapeutics
Cell Proliferation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hedgehog signaling pathway : Development of antagonists for cancer therapy. / Xie, Jingwu.

In: Current Oncology Reports, Vol. 10, No. 2, 03.2008, p. 107-113.

Research output: Contribution to journalArticle

@article{3af376ba7edc496781abdcfe93e2d8c9,
title = "Hedgehog signaling pathway: Development of antagonists for cancer therapy",
abstract = "The hedgehog pathway, initially discovered in Drosophila by two Nobel laureates, Dr. Eric Wieschaus and Dr. Christiane N{\"u}sslein-Volhard, is a major regulator for cell differentiation, tissue polarity, and cell proliferation. Studies from many laboratories - including ours - reveal activation of this pathway in most basal cell carcinomas and nearly one third of extracutaneous human cancers, including medulloblastomas and gastrointestinal and prostate cancers. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. This review discusses the current understanding of the hedgehog signaling pathway and its activation in human cancers. It also discusses putative and confirmed signaling antagonists and their perspectives in therapeutic applications.",
author = "Jingwu Xie",
year = "2008",
month = "3",
doi = "10.1007/s11912-008-0018-7",
language = "English (US)",
volume = "10",
pages = "107--113",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Hedgehog signaling pathway

T2 - Development of antagonists for cancer therapy

AU - Xie, Jingwu

PY - 2008/3

Y1 - 2008/3

N2 - The hedgehog pathway, initially discovered in Drosophila by two Nobel laureates, Dr. Eric Wieschaus and Dr. Christiane Nüsslein-Volhard, is a major regulator for cell differentiation, tissue polarity, and cell proliferation. Studies from many laboratories - including ours - reveal activation of this pathway in most basal cell carcinomas and nearly one third of extracutaneous human cancers, including medulloblastomas and gastrointestinal and prostate cancers. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. This review discusses the current understanding of the hedgehog signaling pathway and its activation in human cancers. It also discusses putative and confirmed signaling antagonists and their perspectives in therapeutic applications.

AB - The hedgehog pathway, initially discovered in Drosophila by two Nobel laureates, Dr. Eric Wieschaus and Dr. Christiane Nüsslein-Volhard, is a major regulator for cell differentiation, tissue polarity, and cell proliferation. Studies from many laboratories - including ours - reveal activation of this pathway in most basal cell carcinomas and nearly one third of extracutaneous human cancers, including medulloblastomas and gastrointestinal and prostate cancers. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. This review discusses the current understanding of the hedgehog signaling pathway and its activation in human cancers. It also discusses putative and confirmed signaling antagonists and their perspectives in therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=40849096112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849096112&partnerID=8YFLogxK

U2 - 10.1007/s11912-008-0018-7

DO - 10.1007/s11912-008-0018-7

M3 - Article

C2 - 18377823

AN - SCOPUS:40849096112

VL - 10

SP - 107

EP - 113

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -